SQZ Biotechnologies (OTCMKTS:SQZB – Get Free Report) is expected to issue its resultson Friday, August 14th. Analysts expect the company to post earnings of ($0.5825) per share and revenue of $4.6620 million for the quarter.
SQZ Biotechnologies Price Performance
Shares of OTCMKTS:SQZB opened at $0.02 on Thursday. SQZ Biotechnologies has a 1 year low of $0.02 and a 1 year high of $0.05. The company has a market cap of $707,760.00, a PE ratio of -0.04 and a beta of 0.33. The stock’s 50-day moving average is $0.02 and its 200 day moving average is $0.02.
SQZ Biotechnologies Company Profile
SQZ Biotechnologies (OTCMKTS:SQZB) is a clinical-stage biotechnology company focused on developing novel cell therapies through its proprietary microfluidic delivery technology. The company’s core “Cell Squeeze” platform temporarily disrupts cell membranes to enable direct intracellular delivery of a wide range of biomolecules, including proteins, peptides and nucleic acids, without relying on viral vectors. This approach is designed to improve manufacturing efficiency, enhance safety profiles and broaden the applicability of cell-based therapies across multiple disease areas.
The company’s pipeline spans oncology, infectious disease and regenerative medicine.
Read More
- Five stocks we like better than SQZ Biotechnologies
- GE Vernova’s AI Power Boom Faces a Profit Test
- Cardinal Health Earnings: Can Perfection Get Priced In Twice?
- Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand
- Legacy Jet Builders Stall While Embraer Accelerates to New Highs
Receive News & Ratings for SQZ Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SQZ Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.
